Immuneering Corporation (IMRX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $502.13M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-406.24K; Retained Earnings (Accumulated Deficit)USD $-311.05M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $500.48M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-241.00K; Retained Earnings (Accumulated Deficit)USD $-293.78M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $498.66M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $81.33K; Retained Earnings (Accumulated Deficit)USD $-280.32M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $496.65M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-268.74M.
Immuneering Corporation Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $502.13M | $-406.24K | $-311.05M | $190.74M | 3 month · $1.63M |
| 2026-03-31 | $0.00 | $500.48M | $-241.00K | $-293.78M | $206.52M | 3 month · $1.64M |
| 2025-12-31 | $0.00 | $498.66M | $81.33K | $-280.32M | $218.48M | 12 month · $6.31M |
| 2025-09-30 | $0.00 | $496.65M | (m) | $-268.74M | $227.98M | 3 month · $1.46M |
| 2025-06-30 | $0.00 | $282.68M | (m) | $-253.78M | $28.94M | 3 month · $1.52M |
| 2025-03-31 | $0.00 | $281.15M | (m) | $-239.34M | $41.84M | 3 month · $1.69M |
| 2024-12-31 | $0.00 | $265.65M | $0.00 | $-224.30M | $41.39M | 12 month · $6.50M |
| 2024-09-30 | $0.00 | $263.93M | $7.84K | $-206.24M | $57.72M | 3 month · $1.64M |
| 2024-06-30 | $0.00 | $257.92M | $0.00 | $-191.65M | $66.31M | 3 month · $1.66M |
| 2024-03-31 | $0.00 | $256.26M | $-1.08K | $-177.57M | $78.72M | 3 month · $1.47M |
| 2023-12-31 | $0.00 | $253.81M | $-778.00 | $-163.26M | $90.58M | 12 month · $5.73M |
| 2023-09-30 | $0.00 | $252.16M | $5.61K | $-148.18M | $104.02M | 3 month · $1.48M |
| 2023-06-30 | $0.00 | $250.66M | $-2.22K | $-135.58M | $115.10M | 3 month · $1.33M |
| 2023-03-31 | $0.00 | $221.15M | $506.00 | $-123.39M | $97.79M | 3 month · $1.27M |
| 2022-12-31 | $0.00 | $219.64M | $-30.12K | $-109.79M | $109.85M | 12 month · $4.06M |
| 2022-09-30 | (m) | $218.55M | $-142.47K | $-96.54M | $121.89M | 3 month · $1.07M |
| 2022-06-30 | (m) | $217.45M | $-181.56K | $-83.70M | $133.59M | 3 month · $1.05M |
| 2022-03-31 | (m) | $216.37M | $-167.40K | $-72.17M | $144.06M | 3 month · $897.65K |
| 2021-12-31 | (m) | $215.28M | $-49.01K | $-59.27M | $155.98M | 12 month · $1.80M |
| 2021-09-30 | (m) | $206.76M | $-4.75K | $-48.49M | $158.29M | 3 month · $636.81K |
| 2021-06-30 | (m) | $4.76M | (m) | $-39.95M | $-35.19M | 3 month · $351.01K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-28.53M | 3 month · $182.22K |
| 2020-12-31 | (m) | $3.25M | (m) | $-25.74M | $-22.48M | 12 month · $1.09M |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-16.86M | 3 month · $310.46K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-12.77M | 3 month · $287.55K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-9.46M | 3 month · $272.14K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-6.53M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |